Skip to main content
x

Recent articles

BeOne tries to repeat the inhibitor-degrader double

Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.

BeOne also needs B7-H4 biomarkers

The company’s BG-C9074 looks competitive, but there are questions about cutoffs and confirmed responses.

Astra looks to confirm Datroway's turnaround

The Avanzar study could read out shortly.

Deals accompany new phase 1 trial starts

First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.

A solid tumour Car-T first?

Satri-cel is filed for gastric cancer approval in China.

TuHura makes its bid for Merkel accelerated approval

The company reckons its immunotherapy could improve on Keytruda.